PHARMACORP RX INC. (“PharmaCorp” or the “Corporation”) (TSXV: PCRX) a Canadian pharmacy services and consolidation platform, is pleased to announce that it has entered into a definitive Retail Collaboration Agreement with McKesson Canada Corporation.
The Retail Collaboration Agreement positions PharmaCorp as a continuity platform for independent pharmacies operating under McKesson Canada’s banners Guardian, I.D.A., and Remedy’sRx, supporting succession planning, exit and value realization for existing owners, while also enabling the next generation of pharmacists to step into ownership as partners with PharmaCorp through PharmaCorp’s co-ownership loan and equity participation program.
Under the agreement, PharmaCorp becomes a collaborative partner for certain McKesson Canada banner pharmacies that are exploring ownership transitions or longer-term capital solutions. The collaboration is designed to provide participating pharmacists with greater optionality as they plan for retirement, partial liquidity, or long-term continuity of their businesses.
Key elements of the Retail Collaboration Agreement include:
- Succession, exit and value realization support: Providing independent Guardian, I.D.A. and Remedy’sRx pharmacy owners with structured pathways for partial or full liquidity aligned with their personal and professional goals.
- Preferred acquisition and partnership framework: A defined process through which PharmaCorp may engage with select McKesson Canada banner pharmacies that are considering ownership transitions or strategic alternatives.
- Banner continuity and stability: Supporting ongoing participation in McKesson’s retail pharmacy banners following a transaction in accordance with applicable banner agreements.
- Next-generation ownership: Enabling younger pharmacists to acquire meaningful equity positions in established banner pharmacies through PharmaCorp’s co-ownership and financing programs.
“This agreement is about preserving continuity of ownership and banners, and supporting the long-term strength of independent pharmacy,” said Alan Simpson, Executive Chair of PharmaCorp. “It’s a practical bridge for today’s owners to plan succession and realize value, while giving the next generation of pharmacists a realistic path into ownership alongside PharmaCorp within trusted McKesson Canada banners.”
“Community pharmacies play a vital role in health care across Canada, and we are deeply committed to supporting their longterm success,” said Tim Smith, Senior Vice President, Marketing and Commercial Operations, McKesson Canada. “By strengthening succession options for our banner pharmacy members, this agreement gives pharmacists confidence as they plan their next chapter – while patients continue to rely on the trusted, local care delivered through a strong community-based pharmacy footprint.”
The Company emphasized that the Retail Collaboration Agreement does not obligate PharmaCorp to complete any transaction, and that all potential acquisitions or partnerships remain subject to customary diligence, valuation discipline, financing considerations and applicable regulatory approvals.
PharmaCorp believes the Retail Collaboration Agreement will further enhance visibility into high-quality acquisition opportunities and support its long-term strategy of building a scaled, operator-aligned Canadian pharmacy platform.
About PharmaCorp Rx Inc.
PharmaCorp Rx Inc. is a Canadian pharmacy services company with a Canada-wide platform for acquiring, co-owning and supporting independent community pharmacies. The Company partners with pharmacists to provide capital, operational expertise, and long-term succession solutions while preserving local ownership, banner affiliation, and patient care standards.
For further information, contact:
For PharmaCorp:
Mr. Alan Simpson
Suite #203, 303 Wellman Lane, Saskatoon, SK S7T 0J1
Tel: (306) 536-3771
Forward-Looking Statements This corporate update contains forward-looking statements, including statements regarding the anticipated benefits of the Retail Collaboration Agreement, future acquisition opportunities, and PharmaCorp’s growth strategy. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially. Readers are cautioned not to place undue reliance on these statements.